The Pharma Data

JANUARY 26, 2021

Gerard Short, MBBS, as Chief Medical Officer (CMO). As CMO, Dr. Short will be responsible for overseeing the clinical development of VarmX’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies.

Clinical Development 40

Clinical Development Medical Schools Therapies Pharmaceuticals 40

The Pharma Data

NOVEMBER 1, 2020

Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

APRIL 12, 2022

vice president and global head of oncology clinical development at AbbVie. “Data obtained from this exploratory analysis holds promise for potential future clinical research,” said Jacqueline S. Dana-Farber Cancer Institute, assistant professor of medicine at Harvard Medical School. Garcia, M.D.,

Medical Schools 52

Medical Schools Trials Disease Clinical Development 52

The Pharma Data

JUNE 7, 2023

“These longer-term results show the durable overall survival benefit of sacituzumab govitecan over traditional chemotherapy in pre-treated HR+/HER2- metastatic breast cancer,” said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School. “At

Medical Schools 40

Medical Schools Therapies Treatment Clinical Development 40

The Pharma Data

DECEMBER 3, 2020

Monti is a pioneer in the research and development of neuroactive steroids known as pherines, which includes VistaGen’s intranasal treatment candidate PH94B for anxiety disorders and PH10 for depression. Zai Lab – Alan Sandler was appointed to the newly created role of president and head of Global Development in Oncology.

Pharmaceuticals 52

Pharmaceuticals Clinical Development Medical Schools Pharmacy 52

The Pharma Data

JANUARY 7, 2021

ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. We are thrilled to join the Chimerix team to help accelerate ONC201 to glioma patients in urgent need of effective treatments. Chief Executive Officer of Oncoceutics.

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

MARCH 17, 2021

In one analysis, the PRO data indicated that most patients (approximately 70-75%) in both arms reported being bothered “a little bit” or “not at all” by treatment-related side effects. Tolaney, MD, MPH, Harvard Medical School, Dana-Farber Cancer Institute. Gallen International Breast Cancer Conference.

Trials 52

Trials Therapies Treatment Pharmacokinetics 52

The Pharma Data

JUNE 25, 2021

Choueiri, director of the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School. “It We hope to build on this important research and provide new treatment options to kidney cancer patients.”. “As It took several decades to achieve this milestone.

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

NOVEMBER 18, 2021

KEYTRUDA Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions. KEYTRUDA Is the First Immunotherapy Approved for the Adjuvant Treatment of These Patients With RCC. Merck’s Focus on Cancer.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52